BRPI0111015B8 - composto antagonista de receptor a2a de adenosina, composição farmacêutica compreendendo o mesmo, seu uso e processos para a preparação de compostos intermediários - Google Patents
composto antagonista de receptor a2a de adenosina, composição farmacêutica compreendendo o mesmo, seu uso e processos para a preparação de compostos intermediáriosInfo
- Publication number
- BRPI0111015B8 BRPI0111015B8 BRPI0111015A BRPI0111015B8 BR PI0111015 B8 BRPI0111015 B8 BR PI0111015B8 BR PI0111015 A BRPI0111015 A BR PI0111015A BR PI0111015 B8 BRPI0111015 B8 BR PI0111015B8
- Authority
- BR
- Brazil
- Prior art keywords
- adenosine
- processes
- optionally substituted
- phenyl
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 229910052799 carbon Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20714300P | 2000-05-26 | 2000-05-26 | |
| US60/207,143 | 2000-05-26 | ||
| PCT/US2001/016954 WO2001092264A1 (en) | 2000-05-26 | 2001-05-24 | Adenosine a2a receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0111015A BR0111015A (pt) | 2005-01-11 |
| BRPI0111015B1 BRPI0111015B1 (pt) | 2017-11-07 |
| BRPI0111015B8 true BRPI0111015B8 (pt) | 2021-05-25 |
Family
ID=22769372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0111015-2 BRPI0111015B8 (pt) | 2000-05-26 | 2001-05-24 | composto antagonista de receptor a2a de adenosina, composição farmacêutica compreendendo o mesmo, seu uso e processos para a preparação de compostos intermediários |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6630475B2 (enExample) |
| EP (1) | EP1283839B1 (enExample) |
| JP (3) | JP4574112B2 (enExample) |
| KR (1) | KR100520907B1 (enExample) |
| CN (2) | CN100384847C (enExample) |
| AR (1) | AR028621A1 (enExample) |
| AT (1) | ATE293627T1 (enExample) |
| AU (2) | AU6808901A (enExample) |
| BR (1) | BRPI0111015B8 (enExample) |
| CA (1) | CA2410237C (enExample) |
| CZ (1) | CZ303790B6 (enExample) |
| DE (1) | DE60110219T2 (enExample) |
| DK (1) | DK1283839T3 (enExample) |
| EC (1) | ECSP024364A (enExample) |
| ES (1) | ES2237576T3 (enExample) |
| HK (1) | HK1049007B (enExample) |
| HU (1) | HU230420B1 (enExample) |
| IL (3) | IL152726A0 (enExample) |
| MX (1) | MXPA02011625A (enExample) |
| MY (1) | MY132006A (enExample) |
| NO (1) | NO325008B1 (enExample) |
| NZ (1) | NZ522326A (enExample) |
| PE (1) | PE20020062A1 (enExample) |
| PL (1) | PL218764B1 (enExample) |
| PT (1) | PT1283839E (enExample) |
| RU (1) | RU2315053C2 (enExample) |
| SI (1) | SI1283839T1 (enExample) |
| SK (1) | SK287748B6 (enExample) |
| TW (1) | TWI288137B (enExample) |
| WO (1) | WO2001092264A1 (enExample) |
| ZA (1) | ZA200208898B (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4574112B2 (ja) * | 2000-05-26 | 2010-11-04 | シェーリング コーポレイション | アデノシンａ２ａレセプターアンタゴニスト |
| CA2459304A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| JP4545437B2 (ja) | 2001-10-15 | 2010-09-15 | シェーリング コーポレイション | アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン |
| FR2832405B1 (fr) * | 2001-11-19 | 2004-12-10 | Sanofi Synthelabo | Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant |
| MXPA04005158A (es) | 2001-11-30 | 2004-08-11 | Schering Corp | Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol. |
| PE20030739A1 (es) | 2001-11-30 | 2003-08-28 | Schering Corp | Antagonistas del receptor de adenosina a2a |
| KR20050044593A (ko) * | 2001-11-30 | 2005-05-12 | 쉐링 코포레이션 | 아데노신 Ａ2ａ 수용체 길항제 |
| KR20150080013A (ko) | 2002-01-28 | 2015-07-08 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료용 조성물 |
| US7064204B2 (en) * | 2002-05-30 | 2006-06-20 | King Pharmacueticals Reserch And Development, Inc. | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| WO2005044245A1 (en) * | 2002-12-19 | 2005-05-19 | Schering Corporation | USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| EP1618109A2 (en) | 2003-04-09 | 2006-01-25 | Biogen Idec MA Inc. | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
| MXPA05011366A (es) * | 2003-04-23 | 2005-11-28 | Schering Corp | Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina. |
| KR20060037252A (ko) * | 2003-06-10 | 2006-05-03 | 교와 핫꼬 고교 가부시끼가이샤 | 불안 장애의 치료 방법 |
| WO2004111004A1 (en) * | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase |
| JP4800216B2 (ja) * | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| WO2005044819A1 (en) * | 2003-10-28 | 2005-05-19 | Schering Corporation | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines |
| ATE377599T1 (de) | 2003-12-01 | 2007-11-15 | Schering Corp | Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen |
| ATE516011T1 (de) * | 2003-12-19 | 2011-07-15 | Schering Corp | Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten |
| DE602005020127D1 (de) | 2004-04-21 | 2010-05-06 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| EP2258372B8 (en) | 2005-06-07 | 2012-12-19 | Kyowa Hakko Kirin Co., Ltd. | A2A antagonists for use in the treatment of motor disorders |
| JP2009508871A (ja) * | 2005-09-19 | 2009-03-05 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとしての２−ヘテロアリール−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジン |
| AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| JP5539717B2 (ja) * | 2006-07-14 | 2014-07-02 | 塩野義製薬株式会社 | オキシム化合物およびその使用 |
| TW200840566A (en) * | 2006-12-22 | 2008-10-16 | Esteve Labor Dr | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| US7723343B2 (en) * | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
| US8669260B2 (en) * | 2008-02-29 | 2014-03-11 | Albert Einstein College Of Medicine Of Yeshiva University | Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof |
| WO2009111449A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
| US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| MX2011000788A (es) * | 2008-07-23 | 2011-03-21 | Kyowa Hakko Kirin Co Ltd | Agente terapeutico para migraña. |
| US20100093702A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| EP2379556A1 (en) | 2008-12-30 | 2011-10-26 | ArQule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| EP2389175A1 (en) | 2009-01-20 | 2011-11-30 | Schering Corporation | Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| EP2405917B1 (en) | 2009-03-13 | 2014-04-23 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| WO2010114894A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| WO2010147941A1 (en) | 2009-06-15 | 2010-12-23 | Marvell World Trade Ltd. | System and methods for gamut bounded saturation adaptive color enhancement |
| WO2011017299A2 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| LT2598482T (lt) | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| US9006177B2 (en) * | 2010-09-24 | 2015-04-14 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| WO2012129381A1 (en) * | 2011-03-22 | 2012-09-27 | Concert Pharmaceuticals Inc. | Deuterated preladenant |
| WO2012127472A1 (en) * | 2011-03-22 | 2012-09-27 | Mapi Pharma Ltd. | Process and intermediates for the preparation of preladenant and related compounds |
| WO2013024474A1 (en) * | 2011-08-18 | 2013-02-21 | Mapi Phrarma Ltd. | Polymorphs of preladenant |
| SI2776394T1 (sl) | 2011-10-20 | 2019-05-31 | Oryzon Genomics, S.A. | Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1 |
| EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| WO2014071512A1 (en) * | 2012-11-06 | 2014-05-15 | Universite Laval | Combination therapy and methods for the treatment of respiratory diseases |
| WO2014101120A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| WO2016081290A1 (en) | 2014-11-18 | 2016-05-26 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
| WO2016126570A1 (en) | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| EP3307067B1 (en) | 2015-06-11 | 2022-11-02 | Merck Sharp & Dohme LLC | Aminopyrazine compounds with a2a antagonist properties |
| WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
| US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
| CN110678472B (zh) * | 2017-03-30 | 2023-01-24 | 伊忒欧斯比利时股份公司 | 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物 |
| WO2018178338A1 (en) * | 2017-03-30 | 2018-10-04 | Iteos Therapeutics | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
| ES2928238T3 (es) | 2018-01-04 | 2022-11-16 | Impetis Biosciences Ltd | Compuestos tricíclicos, composiciones y aplicaciones medicinales de los mismos |
| WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CN108276345A (zh) * | 2018-03-22 | 2018-07-13 | 重庆奥舍生物化工有限公司 | 一种药物中间体嘧啶-5-甲醛的制备方法 |
| CA3095839A1 (en) * | 2018-04-08 | 2019-10-17 | Beigene, Ltd. | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
| US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
| CN108864114B (zh) | 2018-06-04 | 2020-11-06 | 应世生物科技(南京)有限公司 | 选择性a2a受体拮抗剂 |
| JOP20200342A1 (ar) | 2018-07-05 | 2020-12-30 | Incyte Corp | مشتقات بيرازين مدمجة كمثبطات a2a/a2b |
| CN110742893B (zh) * | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
| JOP20210117A1 (ar) | 2018-11-30 | 2023-01-30 | Merck Sharp & Dohme | مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها |
| CR20210336A (es) | 2018-12-20 | 2021-12-06 | Incyte Corp | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2020227156A1 (en) * | 2019-05-03 | 2020-11-12 | Nektar Therapeutics | Adenosine 2 receptor antagonists |
| DE102019116986A1 (de) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate |
| EP3999513A4 (en) * | 2019-07-17 | 2022-12-21 | Teon Therapeutics, Inc. | ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF |
| CN112625050B (zh) | 2019-07-30 | 2021-10-01 | 杭州阿诺生物医药科技有限公司 | 一种a2a和/或a2b受体抑制剂的制备方法 |
| CN112608316B (zh) | 2019-07-30 | 2022-10-21 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类腺苷受体拮抗剂 |
| CN111072675A (zh) * | 2019-12-12 | 2020-04-28 | 广东东阳光药业有限公司 | 含氮稠合三环衍生物及其用途 |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
| CN118812544A (zh) * | 2024-06-19 | 2024-10-22 | 厦门大学 | 一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物 |
| CN118812539B (zh) * | 2024-06-19 | 2025-11-28 | 苏州大学 | 一种5-氨基三唑并嘧啶衍生物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0217748B1 (en) | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
| SU1739850A3 (ru) * | 1987-08-31 | 1992-06-07 | Такеда Кемикал Индастриз, Лтд (Фирма) | Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина |
| IT1264901B1 (it) * | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| AU7237294A (en) | 1993-07-27 | 1995-02-28 | Kyowa Hakko Kogyo Co. Ltd. | Remedy for parkinson's disease |
| IT1277392B1 (it) * | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) * | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| JP4574112B2 (ja) * | 2000-05-26 | 2010-11-04 | シェーリング コーポレイション | アデノシンａ２ａレセプターアンタゴニスト |
| KR20050044593A (ko) * | 2001-11-30 | 2005-05-12 | 쉐링 코포레이션 | 아데노신 Ａ2ａ 수용체 길항제 |
| WO2005044245A1 (en) * | 2002-12-19 | 2005-05-19 | Schering Corporation | USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2005044819A1 (en) * | 2003-10-28 | 2005-05-19 | Schering Corporation | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines |
| ATE377599T1 (de) * | 2003-12-01 | 2007-11-15 | Schering Corp | Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen |
| DE602005020127D1 (de) * | 2004-04-21 | 2010-05-06 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| JP2009508871A (ja) * | 2005-09-19 | 2009-03-05 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとしての２−ヘテロアリール−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジン |
-
2001
- 2001-05-24 JP JP2002500877A patent/JP4574112B2/ja not_active Expired - Lifetime
- 2001-05-24 AT AT01945991T patent/ATE293627T1/de active
- 2001-05-24 HU HU0600239A patent/HU230420B1/hu unknown
- 2001-05-24 AU AU6808901A patent/AU6808901A/xx active Pending
- 2001-05-24 RU RU2002135620/04A patent/RU2315053C2/ru active
- 2001-05-24 TW TW090112461A patent/TWI288137B/zh not_active IP Right Cessation
- 2001-05-24 PT PT01945991T patent/PT1283839E/pt unknown
- 2001-05-24 CZ CZ20023886A patent/CZ303790B6/cs not_active IP Right Cessation
- 2001-05-24 PE PE2001000475A patent/PE20020062A1/es active IP Right Grant
- 2001-05-24 IL IL15272601A patent/IL152726A0/xx unknown
- 2001-05-24 DE DE60110219T patent/DE60110219T2/de not_active Expired - Lifetime
- 2001-05-24 AU AU2001268089A patent/AU2001268089C1/en not_active Expired
- 2001-05-24 CN CNB2006100049297A patent/CN100384847C/zh not_active Expired - Lifetime
- 2001-05-24 BR BRPI0111015-2 patent/BRPI0111015B8/pt not_active IP Right Cessation
- 2001-05-24 DK DK01945991T patent/DK1283839T3/da active
- 2001-05-24 HK HK03101315.3A patent/HK1049007B/en not_active IP Right Cessation
- 2001-05-24 EP EP01945991A patent/EP1283839B1/en not_active Expired - Lifetime
- 2001-05-24 CA CA002410237A patent/CA2410237C/en not_active Expired - Lifetime
- 2001-05-24 CN CNB018134491A patent/CN1247588C/zh not_active Expired - Lifetime
- 2001-05-24 SI SI200130336T patent/SI1283839T1/xx unknown
- 2001-05-24 US US09/865,071 patent/US6630475B2/en not_active Ceased
- 2001-05-24 SK SK1671-2002A patent/SK287748B6/sk not_active IP Right Cessation
- 2001-05-24 WO PCT/US2001/016954 patent/WO2001092264A1/en not_active Ceased
- 2001-05-24 KR KR10-2002-7015699A patent/KR100520907B1/ko not_active Expired - Lifetime
- 2001-05-24 MX MXPA02011625A patent/MXPA02011625A/es active IP Right Grant
- 2001-05-24 ES ES01945991T patent/ES2237576T3/es not_active Expired - Lifetime
- 2001-05-24 AR ARP010102483A patent/AR028621A1/es active IP Right Grant
- 2001-05-24 MY MYPI20012466A patent/MY132006A/en unknown
- 2001-05-24 PL PL360472A patent/PL218764B1/pl unknown
- 2001-05-24 NZ NZ522326A patent/NZ522326A/xx not_active IP Right Cessation
-
2002
- 2002-11-01 ZA ZA200208898A patent/ZA200208898B/en unknown
- 2002-11-10 IL IL152726A patent/IL152726A/en active IP Right Grant
- 2002-11-25 EC EC2002004364A patent/ECSP024364A/es unknown
- 2002-11-25 NO NO20025651A patent/NO325008B1/no not_active IP Right Cessation
-
2003
- 2003-05-30 US US10/448,854 patent/US6897216B2/en not_active Expired - Lifetime
-
2004
- 2004-08-06 US US10/912,834 patent/US7067655B2/en not_active Expired - Lifetime
-
2006
- 2006-05-02 JP JP2006128415A patent/JP4938348B2/ja not_active Expired - Lifetime
-
2007
- 2007-03-16 JP JP2007069618A patent/JP2007145875A/ja not_active Withdrawn
-
2012
- 2012-04-06 US US13/441,140 patent/USRE44205E1/en not_active Expired - Lifetime
- 2012-06-04 IL IL220174A patent/IL220174A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0111015B8 (pt) | composto antagonista de receptor a2a de adenosina, composição farmacêutica compreendendo o mesmo, seu uso e processos para a preparação de compostos intermediários | |
| BR0010060A (pt) | Esteróides 3<244>-hidroxi-3<225>-metoximetil-21-heterocìclo substituìdos com atividade anestésica | |
| BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
| BR9814747A (pt) | Derivados pleuromutilina atuando comoantimicrobianos | |
| BR0114323A (pt) | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto | |
| BR0317524A (pt) | Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| TR200100241T2 (tr) | Nosiseptin reseptörü ORL-1 için yüksek çekim gücü olan ligandlar | |
| BR0209939A (pt) | Composto ou seu sal, éster ou prodroga farmaceuticamente aceitável, formulação farmacêutica, uso do composto ou de seu sal, éster ou prodroga farmaceuticamente aceitável, e, método para tratar câncer | |
| BR0110521A (pt) | Carbamatos azabicìclicos e seu uso como agonistas de receptores de alfa-7 acetilcolina nicotìnico | |
| DK2041133T3 (da) | Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik | |
| BR0102083A (pt) | Uso de derivados de alfa-cetoenamina como ingredientes | |
| BR0316948A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| ES2149305T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso. | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| BRPI0511532A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto | |
| BR9908470A (pt) | Composto, composição farmacêutica, e, processo para tratar condições mediadas pela inegrina avb3 em um mamìfero em necessidade de tal tratamento | |
| BR0116481A (pt) | Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6 | |
| IL195818A0 (en) | Derivatives of 2-benzoyl-imidazopyridines, preparation ,method thereof and use of same in therapeutics | |
| GEP20094697B (en) | Condensed purine derivatives as a1 adenosine receptor antagonists | |
| BR0315958A (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| BR0213907A (pt) | Derivados de heteroarila como ligandos superiores para receptor de nociceptina orl-1 | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR9812404A (pt) | Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina | |
| SE0004462D0 (sv) | Novel method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/11/2017, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 22A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2724 DE 21/03/2023 POR TER SIDO INDEVIDA. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 24/05/2021 |